General Information of Drug (ID: DR4169)
Drug Name
AST-1306
Synonyms Allitinib; Allitinib tosylate
Indication Solid tumour/cancer [ICD11: 2A00-2F9Z] Phase 1 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 448.9 Topological Polar Surface Area 76.1
Heavy Atom Count 32 Rotatable Bond Count 7
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 6
Cross-matching ID
PubChem CID
24739943
ChEBI ID
CHEBI:91467
CAS Number
897383-62-9
TTD Drug ID
D04OLK
Formula
C24H18ClFN4O2
Canonical SMILES
C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl
InChI
InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)
InChIKey
MVZGYPSXNDCANY-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
17-DMAG M1 DM015623
10153393
Unclear - Unclear 1 [2]
Allitinib M1 DM016148
53354142
Oxidation - O-dealkylation 1 [2]
Allitinib M10 DM016809
156028094
Unclear - Unclear 1 [2]
Allitinib M2 DM016833
156596729
Unclear - Unclear 1 [2]
Allitinib M6 DM016156
53630477
Unclear - Unclear 1 [2]
Allitinib M16 DM016752
154572879
Unclear - Unclear 2 [2]
Allitinib M3 DM016831
156596580
Oxidation - Hydroxylation 2 [2]
Allitinib M4 DM016755
154584941
Unclear - Unclear 2 [2]
Allitinib M5 DM016821
156596397
Oxidation - O-dealkylation 2 [2]
Allitinib M5 DM016821
156596397
Unclear - Unclear 2 [2]
Allitinib M7-1 DM016698
141287277
Oxidation - Hydroxylation 2 [2]
Allitinib M9 DM016799
155929095
Unclear - Unclear 2 [2]
Allitinib M12 DM016801
155929104
Unclear - Unclear 3 [2]
Allitinib M15-1 DM016842
156613738
Conjugation - Glucuronidation 3 [2]
Allitinib M8 DM016830
156596574
Conjugation - Sulfation 3 [2]
⏷ Show the Full List of 15  DM(s)
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR009785 AST-1306 Allitinib M1 Oxidation - O-dealkylation CYP3A4 ... [2]
MR009792 AST-1306 Allitinib M6 Unclear - Unclear Unclear [2]
MR009795 AST-1306 Allitinib M14 Unclear - Unclear Unclear [2]
MR009797 AST-1306 Allitinib M10 Unclear - Unclear CYP1A2 ... [2]
MR009799 AST-1306 Allitinib M2 Unclear - Unclear Unclear [2]
MR009786 Allitinib M1 Allitinib M3 Oxidation - Hydroxylation Unclear [2]
MR009788 Allitinib M1 Allitinib M9 Unclear - Unclear Unclear [2]
MR009790 Allitinib M1 Allitinib M4 Unclear - Unclear Unclear [2]
MR009791 Allitinib M1 Allitinib M5 Unclear - Unclear Unclear [2]
MR009798 Allitinib M10 Allitinib M5 Oxidation - O-dealkylation Unclear [2]
MR009796 Allitinib M14 Allitinib M16 Unclear - Unclear Unclear [2]
MR009793 Allitinib M6 Allitinib M7-1 Oxidation - Hydroxylation Unclear [2]
MR009787 Allitinib M3 Allitinib M8 Conjugation - Sulfation Unclear [2]
MR009794 Allitinib M7-1 Allitinib M15-1 Conjugation - Glucuronidation Unclear [2]
MR009789 Allitinib M9 Allitinib M12 Unclear - Unclear Unclear [2]
⏷ Show the Full List of 15 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
Cytochrome P450 2E1 (CYP2E1) DME0013 Homo sapiens
CP2E1_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[2]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[2]
⏷ Show the Full List of 7  DME(s)
References
1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032292)
2 Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.